Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® ...

Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...

Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.

The company relies heavily on acquisitions, with drugs like Fycompa and AGAMREE lacking robust patent protection, posing significant ANDA challenges. AGAMREE's strong launch in the DMD market ...

England’s National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ treatment for Duchenne muscular dystrophy (DMD) Agamree (vamorolone) following a ...

Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy AGAMREE® has been recommended by NICE for treating Duchenne muscular ...

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...

China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and ...

"We are delighted that NICE has recommended AGAMREE for patients with DMD, and we are committed to working closely with the NHS to ensure patients can access AGAMREE as quickly as possible." ...

Pratteln, Switzerland, December 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends AGAMREE® ...

AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern Ireland Santhera will be working closely with ...